Company and Stock Identity

How Pfizer Connects to the Public Market

Company structure
Public company
Market access
Direct listing: NYSE: PFE.
Stock name
PFIZER INC
Ticker and exchange
NYSE: PFE
Research focus
This group asks how far a partnership actually went: a look in a lab, a signed licence, a trial that uses the AI result, or a medicine in a patient. Pfizer is at the signed licence stage with Chai Discovery, which is access to a design tool and not a drug. There is a catch worth knowing before you research this one. The announcement of that licence sits only on a newswire host that blocks automated reading, and Pfizer's own pages block it as well, so this desk has not read the announcement itself and has published no brief on it. If you need the terms, look in a Pfizer filing rather than on a press page.

The federal filer record for PFIZER INC, read on 2026-11-07, gives the ticker PFE on the New York Stock Exchange, central index key 0000078003, incorporation in Delaware, and a head office at 66 Hudson Boulevard East, New York, New York 10001. Its newest filings in that record are a quarterly report and three current reports, all filed on 3 November 2026. No change of control was found. One thing to know about this record: the main Pfizer website, its newsroom and its jobs site all refused this desk on 2026-11-07, answering 403 Forbidden or returning an empty page. The investor overview page is the one Pfizer host that opened. Checked on 2026-11-07.

Dated Market Snapshot

Nov 13, 2026

Last price
$28.895
Change
+0.23%
Previous close
$28.83
52-week high / low
$31.44/$23.62
Market cap
164,697,273,615

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Chai Discovery ... Company source

Chai Discovery raises 400 million dollars at a 3.8 billion dollar valuation

Chai Discovery said on 14 July 2026 that it raised 400 million dollars at a stated valuation of 3.8 billion dollars, in a round led by Index Ventures and Kleiner Perkins alongside Sequoia Capital, Dimension and other investors. The company says the money will expand the compute, data and research behind its models, speed up product development and put the technology in front of more scientists, and that its latest model, Chai-3, is being adopted across Eli Lilly, Pfizer and Novartis.

Why it matters: Spending a round this size on compute and data rather than on a laboratory is the clearest statement of what Chai Discovery is: a model company selling to drug companies, not a drug company. For a research team that is good news on access and bad news on alignment, because the vendor's incentive is adoption across many partners rather than one programme succeeding. A 3.8 billion dollar valuation on no approved product also means the next round depends on partners renewing, so ask about contract length before building a workflow on it.

... Chai Discovery ... Company source

Novartis gets access to Chai Discovery's antibody design models

Chai Discovery announced on 13 July 2026 that Novartis will get access to its AI models, including Chai-3, to support therapeutic antibody discovery across multiple targets. Financial terms were not disclosed, and the announcement gives no number of programs or milestones. Fiona Marshall, Novartis's president of biomedical research, is quoted saying AI is already reshaping how the company discovers medicines and that applying advanced models to problems like antibody design lets it explore a broader range. Joshua Meier, Chai's co-founder and chief executive, is quoted calling it a significant step forward. The announcement also names Pfizer and Eli Lilly as earlier users of Chai's models.

Why it matters: This is an access agreement, which is the lightest kind of deal in this field. A large drug company can hand a model to a research group, try it on a few targets and walk away without ever announcing that it stopped. Nothing here is a result, and nothing here involves a patient. What it does tell a biologics team is that the design models cleared whatever internal review Novartis runs before outside software touches real programs, and that Chai now has three of the largest drug companies on that list. Treat the names as a signal about the software being taken seriously, not as evidence that it works.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: This is an honest gap. The Pfizer jobs site returned an empty page to this desk on 2026-11-07 and the main site answered 403 Forbidden, so no role list, job family or location count could be read. The link here points at the investor overview page, the only Pfizer host that opened, so that a reader has somewhere real to start. Treat this field as unread rather than empty.

Qualification signal: The AI work at a company this size sits inside drug research, not inside a software team, so the useful experience is getting a tool accepted by scientists who have to defend their results to a regulator. Because no role list could be read here, do not guess from a job title. Ask which research unit a role reports into and which programme it supports, and ask whether the tool is built in house or licensed from a partner, because those are different careers with the same name.

Check current roles at Pfizer. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources